CL2021002952A1 - Inhibidores de la autofagia de fenilaminopirimidina amida y métodos de uso de estos - Google Patents
Inhibidores de la autofagia de fenilaminopirimidina amida y métodos de uso de estosInfo
- Publication number
- CL2021002952A1 CL2021002952A1 CL2021002952A CL2021002952A CL2021002952A1 CL 2021002952 A1 CL2021002952 A1 CL 2021002952A1 CL 2021002952 A CL2021002952 A CL 2021002952A CL 2021002952 A CL2021002952 A CL 2021002952A CL 2021002952 A1 CL2021002952 A1 CL 2021002952A1
- Authority
- CL
- Chile
- Prior art keywords
- phenylaminopyrimidine
- amide
- methods
- autophagy inhibitors
- autophagy
- Prior art date
Links
- -1 Phenylaminopyrimidine amide Chemical class 0.000 title 1
- 239000012822 autophagy inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004900 autophagic degradation Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
En el presente documento se describen compuestos que son inhibidores de la autofagia y su uso en el tratamiento de trastornos tales como cánceres
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962846258P | 2019-05-10 | 2019-05-10 | |
US201962846251P | 2019-05-10 | 2019-05-10 | |
US201962911730P | 2019-10-07 | 2019-10-07 | |
US201962911728P | 2019-10-07 | 2019-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002952A1 true CL2021002952A1 (es) | 2022-07-15 |
Family
ID=73046797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002952A CL2021002952A1 (es) | 2019-05-10 | 2021-11-09 | Inhibidores de la autofagia de fenilaminopirimidina amida y métodos de uso de estos |
Country Status (24)
Country | Link |
---|---|
US (2) | US11530206B2 (es) |
EP (2) | EP4342469A2 (es) |
JP (1) | JP2022531801A (es) |
KR (1) | KR20220008873A (es) |
CN (1) | CN114127057A (es) |
AU (2) | AU2020275392B2 (es) |
BR (1) | BR112021022504A2 (es) |
CA (1) | CA3139708A1 (es) |
CL (1) | CL2021002952A1 (es) |
CO (1) | CO2021016768A2 (es) |
DK (1) | DK3966207T3 (es) |
ES (1) | ES2966807T3 (es) |
FI (1) | FI3966207T3 (es) |
IL (1) | IL287787A (es) |
LT (1) | LT3966207T (es) |
MX (1) | MX2021013661A (es) |
PE (1) | PE20220597A1 (es) |
PL (1) | PL3966207T3 (es) |
PT (1) | PT3966207T (es) |
RS (1) | RS65019B1 (es) |
SG (1) | SG11202112336PA (es) |
SI (1) | SI3966207T1 (es) |
TW (1) | TW202108573A (es) |
WO (1) | WO2020231806A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
BR112021012812A2 (pt) | 2018-12-28 | 2021-12-07 | Deciphera Pharmaceuticals Llc | Csf1r inhibitors para uso e tratamento de câncer |
JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
RS65019B1 (sr) | 2019-05-10 | 2024-01-31 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
MX2021013662A (es) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. |
CN114258318A (zh) | 2019-06-17 | 2022-03-29 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
JP2022544234A (ja) | 2019-08-12 | 2022-10-17 | デシフェラ・ファーマシューティカルズ,エルエルシー | 胃腸間質腫瘍を治療するためのリプレチニブ |
JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12d阻害剤 |
KR20220091480A (ko) | 2019-09-24 | 2022-06-30 | 미라티 테라퓨틱스, 인크. | 병용 요법 |
BR112022012106A2 (pt) | 2019-12-20 | 2022-09-20 | Mirati Therapeutics Inc | Inibidores de sos1 |
IL293866A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Compositions of amorphous kinase inhibitors and methods of using them |
IL293864A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea |
MX2023005747A (es) | 2020-11-18 | 2023-07-28 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. |
JP2024516359A (ja) * | 2021-04-07 | 2024-04-15 | ライフアーク | Ulk1/2阻害剤およびその使用 |
TW202332448A (zh) * | 2021-11-15 | 2023-08-16 | 美商艾瑞斯卡公司 | 噻吩ulk1/2抑制劑及其用途 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
WO2024050351A1 (en) * | 2022-09-02 | 2024-03-07 | Deciphera Pharmaceuticals, Llc | Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancer |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
GB9910807D0 (en) | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
JP5230050B2 (ja) | 2000-05-08 | 2013-07-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Hiv複製阻害剤 |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
US7087614B2 (en) | 2001-06-19 | 2006-08-08 | Bristol-Myers Squibb Co. | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
EP1406875B1 (en) | 2001-06-26 | 2013-07-31 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
JP4072615B2 (ja) | 2002-03-05 | 2008-04-09 | 独立行政法人産業技術総合研究所 | 配位子を有する複素環化合物及びその製造方法、及びこの複素環化合物を用いる金属元素の固定化膜 |
NZ539823A (en) | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
EP1781659B1 (en) | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
JP4886511B2 (ja) | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法 |
ES2365223T3 (es) | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos. |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EA011671B1 (ru) | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
EP1835934A4 (en) | 2004-12-23 | 2010-07-28 | Deciphera Pharmaceuticals Llc | ENZYME MODULATORS AND TREATMENTS |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
CN101484433A (zh) | 2006-02-15 | 2009-07-15 | 艾博特公司 | 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
US20090312321A1 (en) | 2006-05-15 | 2009-12-17 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
KR20090019011A (ko) | 2006-06-15 | 2009-02-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 단백질 키나아제 c-알파의 억제제로서의 2-아닐리노-4-(헤테로사이클릭)아미노-피리미딘 |
US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
CN101611035A (zh) | 2006-12-28 | 2009-12-23 | 大正制药株式会社 | 吡唑并嘧啶化合物 |
EP2146717A4 (en) | 2007-04-20 | 2010-08-11 | Deciphera Pharmaceuticals Llc | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYOLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES |
JP2011500727A (ja) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Gpr119の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用 |
US20100056524A1 (en) | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR101892989B1 (ko) | 2008-06-27 | 2018-08-30 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
JP5444365B2 (ja) | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ,エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
CA2785738A1 (en) | 2009-12-30 | 2011-07-07 | Avila Therapeutics, Inc. | Ligand-directed covalent modification of protein |
WO2011139891A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
ES2475741T3 (es) | 2010-04-29 | 2014-07-11 | Deciphera Pharmaceuticals, Llc | Ciclopropil dicarboxamidas y análogos que presentan actividades antic�ncer y antiproliferativas |
ES2691673T3 (es) | 2011-02-17 | 2018-11-28 | Cancer Therapeutics Crc Pty Limited | Inhibidores de Fak |
CN104302292A (zh) | 2011-11-22 | 2015-01-21 | 德西费拉制药有限责任公司 | 表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物 |
JP6180426B2 (ja) | 2011-11-29 | 2017-08-16 | ジェネンテック, インコーポレイテッド | パーキンソン病の処置のためのキナーゼlrrk2モジュレーターとしての2−(フェニル又はピリド−3−イル)アミノピリミジン誘導体 |
EP2807152B1 (en) | 2011-11-29 | 2017-07-19 | Genentech, Inc. | Aminopyrimidine derivatives as lrrk2 modulators |
MX353254B (es) | 2011-11-30 | 2018-01-05 | Genentech Inc | Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2). |
AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
US9309224B2 (en) | 2013-03-15 | 2016-04-12 | Deciphera Pharmaceuticals, Llc. | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
KR102628583B1 (ko) | 2013-03-15 | 2024-01-25 | 데시페라 파마슈티칼스, 엘엘씨. | 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 |
US9012635B2 (en) | 2013-03-15 | 2015-04-21 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
WO2014145023A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
CN105228620B (zh) | 2013-03-15 | 2020-09-04 | 德西费拉制药有限责任公司 | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 |
US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
EP3019491A4 (en) | 2013-07-09 | 2016-12-21 | Dana Farber Cancer Inst Inc | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE |
WO2015039613A1 (zh) | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
AU2014323777C1 (en) | 2013-09-18 | 2018-04-26 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of BTK and/or JAK3 kinases |
SI3057943T1 (en) | 2013-10-18 | 2018-08-31 | Eisai R&D Management Co., Ltd. | Pyrimidine FGFR4 Inhibitors |
WO2015061247A2 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
US20150284341A1 (en) | 2014-04-07 | 2015-10-08 | Catylix, Inc. | Fluoroalkyl-substituted derivatives of pyridine, pyrimidine, and pyrazine |
ES2914099T3 (es) | 2014-08-25 | 2022-06-07 | Salk Inst For Biological Studi | Inhibidores novedosos de ULK1 y métodos de uso de los mismos |
US10336734B2 (en) | 2015-08-02 | 2019-07-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ACK1/TNK2 tyrosine kinase |
WO2017066428A1 (en) | 2015-10-13 | 2017-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Brd4-kinase inhibitors as cancer therapeutics |
WO2018160774A1 (en) | 2017-02-28 | 2018-09-07 | The General Hospital Corporation | Uses of pyrimidopyrimidinones as sik inhibitors |
MX2019014343A (es) | 2017-05-30 | 2020-08-03 | Deciphera Pharmaceuticals Inc | Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-n aftiridin-3-il]-2-fluorofenil]-3-fenilurea y analogos para el tratamiento de canceres asociados con anomalias geneticas en el receptor alfa del factor de crecimiento derivado de plaquetas. |
CN111886006A (zh) | 2018-01-31 | 2020-11-03 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
CN112189012B (zh) | 2018-04-10 | 2024-02-13 | 神经孔疗法股份有限公司 | 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物 |
BR112021012812A2 (pt) | 2018-12-28 | 2021-12-07 | Deciphera Pharmaceuticals Llc | Csf1r inhibitors para uso e tratamento de câncer |
RS65019B1 (sr) | 2019-05-10 | 2024-01-31 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene |
MX2021013662A (es) | 2019-05-10 | 2022-03-11 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos. |
CN114258318A (zh) | 2019-06-17 | 2022-03-29 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
-
2020
- 2020-05-08 RS RS20231266A patent/RS65019B1/sr unknown
- 2020-05-08 AU AU2020275392A patent/AU2020275392B2/en active Active
- 2020-05-08 DK DK20729420.8T patent/DK3966207T3/da active
- 2020-05-08 CA CA3139708A patent/CA3139708A1/en active Pending
- 2020-05-08 SG SG11202112336PA patent/SG11202112336PA/en unknown
- 2020-05-08 TW TW109115468A patent/TW202108573A/zh unknown
- 2020-05-08 PE PE2021001870A patent/PE20220597A1/es unknown
- 2020-05-08 KR KR1020217040559A patent/KR20220008873A/ko active Search and Examination
- 2020-05-08 JP JP2021566469A patent/JP2022531801A/ja active Pending
- 2020-05-08 LT LTEPPCT/US2020/032087T patent/LT3966207T/lt unknown
- 2020-05-08 CN CN202080049700.3A patent/CN114127057A/zh active Pending
- 2020-05-08 BR BR112021022504A patent/BR112021022504A2/pt unknown
- 2020-05-08 US US16/870,384 patent/US11530206B2/en active Active
- 2020-05-08 PT PT207294208T patent/PT3966207T/pt unknown
- 2020-05-08 ES ES20729420T patent/ES2966807T3/es active Active
- 2020-05-08 EP EP23206773.6A patent/EP4342469A2/en active Pending
- 2020-05-08 WO PCT/US2020/032087 patent/WO2020231806A1/en active Application Filing
- 2020-05-08 PL PL20729420.8T patent/PL3966207T3/pl unknown
- 2020-05-08 FI FIEP20729420.8T patent/FI3966207T3/fi active
- 2020-05-08 EP EP20729420.8A patent/EP3966207B1/en active Active
- 2020-05-08 MX MX2021013661A patent/MX2021013661A/es unknown
- 2020-05-08 SI SI202030312T patent/SI3966207T1/sl unknown
-
2021
- 2021-11-02 IL IL287787A patent/IL287787A/en unknown
- 2021-11-09 CL CL2021002952A patent/CL2021002952A1/es unknown
- 2021-12-10 CO CONC2021/0016768A patent/CO2021016768A2/es unknown
-
2022
- 2022-06-06 US US17/833,272 patent/US20230039712A1/en active Pending
-
2023
- 2023-10-17 AU AU2023251416A patent/AU2023251416A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SI3966207T1 (sl) | 2023-12-29 |
PL3966207T3 (pl) | 2024-03-04 |
JP2022531801A (ja) | 2022-07-11 |
FI3966207T3 (fi) | 2023-11-30 |
SG11202112336PA (en) | 2021-12-30 |
EP4342469A2 (en) | 2024-03-27 |
TW202108573A (zh) | 2021-03-01 |
LT3966207T (lt) | 2023-12-11 |
IL287787A (en) | 2022-01-01 |
ES2966807T3 (es) | 2024-04-24 |
US11530206B2 (en) | 2022-12-20 |
AU2020275392B2 (en) | 2023-09-14 |
CA3139708A1 (en) | 2020-11-19 |
AU2023251416A1 (en) | 2023-11-09 |
EP3966207A1 (en) | 2022-03-16 |
WO2020231806A1 (en) | 2020-11-19 |
KR20220008873A (ko) | 2022-01-21 |
PE20220597A1 (es) | 2022-04-22 |
US20200354352A1 (en) | 2020-11-12 |
EP3966207B1 (en) | 2023-11-01 |
DK3966207T3 (da) | 2023-12-18 |
AU2020275392A1 (en) | 2021-12-02 |
CO2021016768A2 (es) | 2022-04-08 |
RS65019B1 (sr) | 2024-01-31 |
MX2021013661A (es) | 2022-03-11 |
US20230039712A1 (en) | 2023-02-09 |
CN114127057A (zh) | 2022-03-01 |
PT3966207T (pt) | 2023-12-20 |
BR112021022504A2 (pt) | 2022-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002952A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y métodos de uso de estos | |
CO2021016765A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
ECSP20069404A (es) | Piridazinonas como inhibidoras de parp7 | |
CL2018000128A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
CO2022000260A2 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso | |
CY1123972T1 (el) | Θεραπεια συνδυασμου για καρκινο | |
CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
CL2018000101A1 (es) | Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469) | |
CO2017007671A2 (es) | Composiciones para modular la expresión de c9orf72 | |
CO2020014345A2 (es) | Anticuerpos específicos para gucy2c y sus usos | |
CL2018000140A1 (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
CL2019001043A1 (es) | Anticuerpos anti-il-33 y usos de los mismos. | |
CL2019001336A1 (es) | Inhibidores de la magl. | |
CL2018002810A1 (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
ECSP20077106A (es) | Régimen de dosificación para el tratamiento de trastornos relacionados con pi3k | |
CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
CL2021002182A1 (es) | Formulación de anticuerpos terapéuticos | |
AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
UY36010A (es) | NUEVOS COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZINA-5,8-DIONA | |
DOP2019000082A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
AR119973A1 (es) | Composiciones y métodos de anticuerpos anti-cd39 |